L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
HCS PHARMA développe et commercialise des produits de culture cellulaire 3D basés sur sa technologie disruptive, exclusive et propriétaire BIOMIMESYS, hydrosquelette qui permet de reproduire la matrice extracellulaire de façon organe-spécifique.
Lille, Hauts-de-France, France
Envoyer un message
During the last BIO Asia-Taiwan event HCS Pharma was awarded by the National Health Research Institute (NHRI) as a key company (關鍵新創) in the “Partnering and Medical Innovation” category (攜手同行暨創醫獎) for the BIOMIMESYS® technology. BIOMIMESYS® was recognized as a groundbreaking technology, allowing to reproduce any type of healthy or cancerous organ/tissue ECM thanks to its unique asset combining both behavior (solid scaffold and hydrogel behavior). This unique Hyaluronic Acid-based hydroscaffold is the only one reproducing the porosity, stiffness, composition of in vivo ECM.
We were very happy to be present at BIO Asia-Taiwan from 4 to 7 November as a member of the National Health Research Institutes (NHRI) Technology Transfer & Incubation Center (TTIC). Joseph CHOU, the representative of HCS Pharma Taïwan, and his team have presented our products BIOMIMESYS® and our last developments. They had a lot of visitors interested by our products and many promising contacts were made.
We are really happy for such recognition in Taïwan et we warmly thanks the entire HCS Pharma Taiwan team.
It's a geat honor for us to be present at the BIO Asia-Taiwan event in Taipei as a member of the National Health Research Institutes (NHRI) Technology Transfer & Incubation Center (TTIC). Our technology BIOMIMESYS® is in high demand in Asia for personalised medicine and cellular therapy. We are very happy to accelerate our market developement thanks to our partner Tokyo Future Style Taiwan, Inc.
As you might know, October is the Breast Cancer Awareness Month, an annual campaign to raise awareness about the impact of breast cancer. Research is the key tool to fight this disease and we are very happy to collaborate with amazing research teams in this fight.
Since last year, our work on breast cancer reserach has progressed through different collaborations:
What a great emulation to fight breast cancer! Thanks a lot for their commitment…
Do you want to help researchers fight breast cancer? Find your national organization (like the National Breast Cancer Foundation in USA or Ligue contre le Cancer in France) or other associations, and please donate. It’s fast, easy and it is a concrete act in this endeavor. Thank you!
Earlier this month, the European parliament has voted for accelerating the limitation (end?) of animal testing for research, regulatory and education purposes. As a reminder, the testing ban on finished cosmetic products applies since 11 September 2004 and the testing ban on ingredients (or combination of ingredients) applies since 11 March 2009.
However, animals are still being used for other purposes. According to the principles of the 3Rs (developed over 50 years ago), the use of animals should be Replaced (by alternative methods, as much as possible), Reduced (less animals for tests) and Refined (i.e. minimizing animal suffering) whenever possible.
With this new vote, the EU parliament appeals for a research policy in favor of valuable, predictive alternative methods, since the 3Rs should be applied without decreasing the protection of human health and of the environment. Indeed, more research is needed to propose, in particular, relevant in vitro models that can predict human outcomes. In the frame of the pharmaceutical industry, the idea would be to get models that effectively mimic the complexity of human tissues/organs, allowing to conclude about the toxicity and efficiency of drugs.
Lately, new in vivo-like 3D in vitro models – alone or combined with complex systems like microfluidics, bioMEMs, etc. should pave the way to more predictive and animal-free science.
In HCS Pharma, we are all committed to propose such alternatives, thanks to the use of BIOMIMESYS® in 3D cell culture, and related in vitro models for brain, adipose, liver and cancer tissues… In this frame, we are also collaborating with a great panel of scientists in academic laboratories: thanks a lot for your work in this direction!
Do you want to talk about possible alternatives? Contact us!
We are pleased to announce that HCS Pharma secured 20 Million EUR capital commitment from GEM group following the public listing of the company shares on a European stock exchange. We are under the IPO process that we will finalize in the next coming months. The proceeds of IPO with GEM commitment will be used to accelerate the development of the range of BIOMIMESYS® products and their commercialization in the global market.
Débute le 08/2014
HCS Pharma founded by Nathalie MAUBON as a CRO
fund raising with FINOVAM & NFA: seed
New site with 250 m² of space with: - 2 cell culture labs - 1 automation lab with 1 robotic platform